[Does the SOLENCE application improve the quality of life of patients with polyendocrine metabolic ovarian syndrome?].

OBJECTIVE: A digital health application dedicated to polyendocrine metabolic ovarian syndrome (PMOS), the SOLENCE application, was offered to patients diagnosed with PMOS according to the Rotterdam criteria at a University Hospital. We seek to evaluate the impact of the SOLENCE application on patients' quality of life. METHODS : Questionnaires assessing the quality of life of PMOS patients, their anxiety, depression, and sexual satisfaction before and after 6 months of using the app were compared. The inclusion period was from November 2023 to December 2024. The questionnaire consisted of four validated sub-questionnaires: PCOSQOL (Polycystic Ovary Syndrome Quality of Life), HADS (Hospital Anxiety and Depression Scale), ASEX (Arizona Sexual Experience Scale), and FACT-G7 (Functional Assessment of Cancer Therapy - General - 7 Item Version).

RESULTS: A total of 54 patients were included. After comparing the questionnaires before and after using the app, only the FACT-G7 questionnaire, which assesses overall quality of life in the monitoring of chronic diseases showed a statistically significant worsening. The lack of statistical power due to the small sample size may partially explain these results. In addition, the patients who logged in most frequently felt that the SOLENCE app could have a place in the medical monitoring of PMOS patients. CONCLUSION : The SOLENCE app does not appear to provide any benefit to our patients with PMOS. Further studies are needed to investigate the improvement in PMOS symptoms between users and non-users of the app, which has since been updated to offer more personalized content.